Indoco Remedies Holds 78th AGM, Declares ₹0.20 Final Dividend for FY25
The announcement details the routine proceedings of the Annual General Meeting and includes the declaration of a small final dividend of ₹0.20 per equity share, which has a relatively low financial impact.
The company declared a final dividend of ₹0.20 per equity share for the financial year ended March 31, 2025, which is a positive return to shareholders.
Indoco Remedies Limited convened its 78th Annual General Meeting (AGM) on Thursday, 11th September, 2025, at 10:30 a.m. through Video Conferencing (VC) / Other Audio Video Means (OAVM). * Mr. Suresh G Kare, Chairman, chaired the meeting, which was attended by key directors and senior officials, including Ms. Aditi Panandikar (Managing Director) and Mr. Sundeep V. Bambolkar (Jt. Managing Director). * Ms. Aditi Panandikar, Managing Director, apprised the members about the company's performance and future prospects. * Shareholders considered and adopted the audited standalone and consolidated financial statements for the financial year ended March 31, 2025. * A final dividend of ₹0.20 (Twenty Paise Only) per equity share for the financial year ended March 31, 2025, was declared. * Other resolutions passed included: * Re-appointment of Dr. Anand M Nadkarni as a Director. * Ratification of the remuneration of Cost Auditors for the financial year 2025-2026. * Appointment of A. Y. Sathe & Co. as Secretarial Auditor and fixing their remuneration. * Re-appointment of Dr. (Ms.) Vasudha V Kamat as an Independent Director. * Re-appointment of Mr. Abhijit Y Gore as an Independent Director. * The meeting included a question and answer session where management responded to shareholder queries. * The AGM commenced at 10:30 a.m. and concluded at 11:54 a.m., including time for e-voting.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under agm-egm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.